Coronary Artery DiseaseNCT07614763
To Study and Explore the Predictive Effect of Insulin Resistance-related Indicators on In-stent Restenosis After Coronary Stent Implantation
An observational study of Coronary Artery Disease and In-stent Restenosis, run by Qilu Hospital of Shandong University at 1 site in China.
Trial summary
Based on previous studies on insulin resistance and cardiovascular diseases, we believe that the insulin resistance metabolic score also has certain predictive value for the prognosis of in-stent restenosis after coronary stent implantation. Read more about this study
- Who is it for?
- Ages 45 years and older
- Conditions the study is for
- Coronary Artery Disease, In-stent Restenosis
- What is being tested?
- Observational studies do not design intervention measures
- How many people
- 1,000 participants
- Where
- 1 siteChina
- Study dates
- 1 Jan 2022to 1 Nov 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 45 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: We retrospectively collected the clinical data of patients with recurrent chest pain after PCI and requiring repeated angiography from January 2022 to November 2025, which were obtained from electronic medical records.
Who may be able to join
- Age ≥45 years
- Patients with a history of percutaneous coronary intervention (PCI) with stent implantation
- Patients who underwent repeat coronary angiography during follow-up
- Complete clinical data available, including echocardiography, 24-hour ambulatory electrocardiogram, NT-proBNP, liver and kidney function tests, and blood biochemical tests
Who cannot join
- Previous coronary artery bypass grafting
- Lesions treated only with balloon angioplasty without stent implantation
- Clinical manifestations of heart failure, structural cardiomyopathy, congenital heart disease, or significant valvular heart disease
- Severe hepatic or renal dysfunction, such as estimated glomerular filtration rate <30 mL/min/1.73 m²
- Incomplete clinical or angiographic data
Trial locations and contacts
1 site in 1 country.
About this study
Official title: The Predictive Effect of Insulin Resistance Metabolic Score on In-stent Restenosis After Coronary Stent Implantation
Based on previous studies on insulin resistance and cardiovascular diseases, we believe that the insulin resistance metabolic score also has certain predictive value for the prognosis of in-stent restenosis after coronary stent implantation. The main purpose of this study is to explore the predictive effect of the insulin resistance metabolic score on in-stent restenosis after coronary stent implantation and to discuss a reasonable control level.
Read the detailed description
Coronary atherosclerotic heart disease, especially acute myocardial infarction, remains the leading cause of death worldwide. Despite the development and improvement of percutaneous coronary intervention (PCI) and drug therapy, which have significantly improved survival rates and clinical outcomes, the unresolved problem of in-stent restenosis (ISR) remains a key factor limiting the therapeutic effect. Therefore, identifying and studying the risk factors and formation mechanisms of in-stent restenosis is an important clinical step in preventing and treating in-stent restenosis. Moreover, an increasing number of studies have shown that IR may have a significant impact on the occurrence and progression of in-stent restenosis (ISR). The traditional quantitative techniques for assessing IR are limited by cost, time, and manpower, while new biomarkers overcome these limitations and become a clinically feasible alternative with cardiovascular disease prediction capabilities. However, there is currently no large amount of data to prove the relationship between metabolic syndrome-insulin resistance (METS-IR) and in-stent restenosis (ISR). Therefore, we designed a retrospective study on patients with recurrent chest pain after percutaneous coronary intervention to evaluate the potential association between subepithelial restenosis (ISR) and metabolic syndrome-insulin resistance (METS-IR), thereby providing a basis for evaluating METS-IR as a possible risk indicator for ISR in patients after percutaneous coronary intervention.
- Conditions
- Coronary Artery Disease, In-stent Restenosis
- Being tested
- Observational studies do not design intervention measures
- Medical subject headings
- Coronary Artery Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Observational studies do not design intervention measuresOther
Observational studies do not design intervention measures
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of in-stent restenosis greater than 50% and greater than 70% assessed by follow-up coronary angiography
In-stent restenosis was defined as recurrent luminal diameter stenosis within the stented segment or within 5 mm proximal or distal to the stent edges, as determined by follow-up coronary angiography. Percent diameter stenosis was used to quantify the severity of restenosis. Participants will be classified according to whether they had in-stent restenosis greater than 50% and greater than 70%, and the outcome will be summarized as the number and percentage of participants in each category.
Measured: During follow-up coronary angiography within 6-60 months after PCI
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 May 2026
- Study start1 Jan 2022
- Primary completion1 Nov 2025
- Study completion1 Nov 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Coronary Artery DiseaseStudies of the same condition, open and under way.
- More trials run by Qilu Hospital of Shandong UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 1,000 participants (actual)
Sponsor and investigators
- Lead sponsor
- Qilu Hospital of Shandong University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07614763
- Sponsor's protocol ID
- KYLL-2025-11-064
- Status last verified
- Jan 2026
- First submitted
- 6 Feb 2026
- Last updated
- 29 May 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 29 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Predictive Effect of Insulin Resistance Metabolic Score on In-stent Restenosis After Coronary Stent Implantation
- ClinicalTrials.gov ID
- NCT07614763
- Acronym / sponsor ID
- KYLL-2025-11-064
- Conditions
- Coronary Artery Disease, In-stent Restenosis
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 1,000 participants (actual)
- Lead sponsor
- Qilu Hospital of Shandong UniversityUniversity, hospital or other
- Study start
- 1 Jan 2022 (actual)
- Primary completion
- 1 Nov 2025 (actual)
- Study completion
- 1 Nov 2025 (actual)
- First posted
- 29 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Based on previous studies on insulin resistance and cardiovascular diseases, we believe that the insulin resistance metabolic score also has certain predictive value for the prognosis of in-stent restenosis after coronary stent implantation. The main purpose of this study is to explore the predictive effect of the insulin resistance metabolic score on in-stent restenosis after coronary stent implantation and to discuss a reasonable control level.
Detailed description
Coronary atherosclerotic heart disease, especially acute myocardial infarction, remains the leading cause of death worldwide. Despite the development and improvement of percutaneous coronary intervention (PCI) and drug therapy, which have significantly improved survival rates and clinical outcomes, the unresolved problem of in-stent restenosis (ISR) remains a key factor limiting the therapeutic effect. Therefore, identifying and studying the risk factors and formation mechanisms of in-stent restenosis is an important clinical step in preventing and treating in-stent restenosis. Moreover, an increasing number of studies have shown that IR may have a significant impact on the occurrence and progression of in-stent restenosis (ISR). The traditional quantitative techniques for assessing IR are limited by cost, time, and manpower, while new biomarkers overcome these limitations and become a clinically feasible alternative with cardiovascular disease prediction capabilities. However, there is currently no large amount of data to prove the relationship between metabolic syndrome-insulin resistance (METS-IR) and in-stent restenosis (ISR). Therefore, we designed a retrospective study on patients with recurrent chest pain after percutaneous coronary intervention to evaluate the potential association between subepithelial restenosis (ISR) and metabolic syndrome-insulin resistance (METS-IR), thereby providing a basis for evaluating METS-IR as a possible risk indicator for ISR in patients after percutaneous coronary intervention.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
Who may qualify
- Ages
- 45 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- We retrospectively collected the clinical data of patients with recurrent chest pain after PCI and requiring repeated angiography from January 2022 to November 2025, which were obtained from electronic medical records.
Key inclusion criteria (4 listed)
- Age ≥45 years
- Patients with a history of percutaneous coronary intervention (PCI) with stent implantation
- Patients who underwent repeat coronary angiography during follow-up
- Complete clinical data available, including echocardiography, 24-hour ambulatory electrocardiogram, NT-proBNP, liver and kidney function tests, and blood biochemical tests
Key exclusion criteria (5 listed)
- Previous coronary artery bypass grafting
- Lesions treated only with balloon angioplasty without stent implantation
- Clinical manifestations of heart failure, structural cardiomyopathy, congenital heart disease, or significant valvular heart disease
- Severe hepatic or renal dysfunction, such as estimated glomerular filtration rate <30 mL/min/1.73 m²
- Incomplete clinical or angiographic data
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Observational studies do not design intervention measuresObservational studies do not design intervention measures | Other | – |
Primary outcome
Incidence of in-stent restenosis greater than 50% and greater than 70% assessed by follow-up coronary angiography
Time frame: During follow-up coronary angiography within 6-60 months after PCI
In-stent restenosis was defined as recurrent luminal diameter stenosis within the stented segment or within 5 mm proximal or distal to the stent edges, as determined by follow-up coronary angiography. Percent diameter stenosis was used to quantify the severity of restenosis. Participants will be classified according to whether they had in-stent restenosis greater than 50% and greater than 70%, and the outcome will be summarized as the number and percentage of participants in each category.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 May 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Coronary Artery Disease
Not yet recruitingObservational study
Assessment of Transnational Performance of the Universal Cardiac Surgical Risk Score Across International Sites
Heart Valve Diseases, Cardiac Surgical Procedures
Not yet recruiting
Sirolimus-Coated Versus Paclitaxel-Coated Balloon for Recurrent Coronary In-Stent Restenosis After Prior Paclitaxel-Coated Balloon Treatment (SPRIT)
Coronary In-stent Restenosis, Coronary Artery Disease
RecruitingObservational study
Norepinephrine in the Management of General Anesthesia-Induced Arterial Hypotension in Chronic Heart Failure Patients
Hypotension
Active, not recruitingObservational study
The CoPenHagen PREeClampsia and cardIOvascUlar diSease Study
Pre-Eclampsia, Atherosclerosis
RecruitingObservational study
Cardiovascular Risk Assessment For Kidney Transplantation - Utility of Computed Tomography Coronary Angiography in the Assessment of Patients Awaiting Kidney Transplantation
Cardiovascular Diseases, Kidney Transplant; Complications
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Coronary Artery Disease and In-stent Restenosis, run by Qilu Hospital of Shandong University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 29 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of in-stent restenosis greater than 50% and greater than 70% assessed by follow-up coronary angiography (time frame: During follow-up coronary angiography within 6-60 months after PCI). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 May 2026.